M971BBz

M971BBz is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the National Cancer Institute (NCI) for the treatment of relapsed or refractory hairy cell leukemia (HCL) and its variant (HCL-v). The therapy involves the genetic modification of a patient's own T cells to express a CAR targeting the CD22 antigen, a cell surface protein consistently expressed on malignant hairy cells. The M971BBz construct utilizes a fully human single-chain variable fragment (scFv) derived from the M971 antibody, which binds to a proximal epitope of CD22, coupled with a 4-1BB (CD137) costimulatory domain and a CD3-zeta signaling chain. This second-generation CAR design aims to promote T-cell activation, expansion, and long-term persistence to effectively eliminate CD22-positive leukemic cells. It is currently being evaluated in a Phase I dose-escalation study.

Other names

CD22CARTCD-22CARTCD 22CARTanti-CD22 CAR T-cell therapyanti-CD-22 CAR T-cell therapyanti-CD 22 CAR T-cell therapyCD22-targeted CAR T-cell therapyCD-22-targeted CAR T-cell therapyCD 22-targeted CAR T-cell therapyM971-BBzM-971-BBzM 971-BBz